Edwards Lifesciences Corp., adjusted current assets

US$ in thousands

	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
As Reported
Current assets	3,180,700)	3,091,000)	2,984,000)	2,286,900)	2,532,100)
Adjustments
Add: Allowance for doubtful accounts	9,300)	9,600)	8,700)	8,900)	8,500)
After Adjustment
Adjusted current assets	3,190,000)	3,100,600)	2,992,700)	2,295,800)	2,540,600)

Download chart

Edwards Lifesciences Corp., adjusted total assets

US$ in thousands

	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
As Reported
Total assets	8,502,600)	7,237,100)	6,488,100)	5,323,700)	5,695,800)
Adjustments
Add: Operating lease right-of-use asset (before adoption of FASB Topic 842)¹	—)	—)	—)	82,604)	67,539)
Add: Allowance for doubtful accounts	9,300)	9,600)	8,700)	8,900)	8,500)
Less: Deferred tax assets²	246,700)	230,900)	172,200)	174,000)	213,600)
After Adjustment
Adjusted total assets	8,265,200)	7,015,800)	6,324,600)	5,241,204)	5,558,239)

¹ Operating lease right-of-use asset (before adoption of FASB Topic 842). See details »

² Deferred tax assets. See details »

Download chart

Edwards Lifesciences Corp., adjusted total liabilities

US$ in thousands

	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
As Reported
Total liabilities	2,666,700)	2,662,800)	2,339,800)	2,183,300)	2,739,600)
Adjustments
Add: Operating lease liability (before adoption of FASB Topic 842)¹	—)	—)	—)	82,604)	67,539)
Less: Deferred tax liabilities²	24,600)	28,100)	36,800)	9,000)	27,600)
After Adjustment
Adjusted total liabilities	2,642,100)	2,634,700)	2,303,000)	2,256,904)	2,779,539)

¹ Operating lease liability (before adoption of FASB Topic 842). See details »

² Deferred tax liabilities. See details »

Download chart

Edwards Lifesciences Corp., adjusted stockholders’ equity

US$ in thousands

	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
As Reported
Stockholders’ equity	5,835,900)	4,574,300)	4,148,300)	3,140,400)	2,956,200)
Adjustments
Less: Net deferred tax assets (liabilities)¹	222,100)	202,800)	135,400)	165,000)	186,000)
Add: Allowance for doubtful accounts	9,300)	9,600)	8,700)	8,900)	8,500)
After Adjustment
Adjusted stockholders’ equity	5,623,100)	4,381,100)	4,021,600)	2,984,300)	2,778,700)

¹ Net deferred tax assets (liabilities). See details »

Download chart

Edwards Lifesciences Corp., adjusted capitalization table

US$ in thousands

	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
As Reported
Short-term debt	—)	—)	—)	—)	598,000)
Long-term debt	595,700)	595,000)	594,400)	593,800)	438,400)
Total reported debt	595,700)	595,000)	594,400)	593,800)	1,036,400)
Stockholders’ equity	5,835,900)	4,574,300)	4,148,300)	3,140,400)	2,956,200)
Total reported capital	6,431,600)	5,169,300)	4,742,700)	3,734,200)	3,992,600)
Adjustments to Debt
Add: Operating lease liability (before adoption of FASB Topic 842)¹	—)	—)	—)	82,604)	67,539)
Add: Operating lease liabilities, current portion²	25,500)	27,200)	25,500)	—)	—)
Add: Operating lease liabilities, long-term portion³	69,100)	72,700)	58,900)	—)	—)
Adjusted total debt	690,300)	694,900)	678,800)	676,404)	1,103,939)
Adjustments to Equity
Less: Net deferred tax assets (liabilities)⁴	222,100)	202,800)	135,400)	165,000)	186,000)
Add: Allowance for doubtful accounts	9,300)	9,600)	8,700)	8,900)	8,500)
Adjusted stockholders’ equity	5,623,100)	4,381,100)	4,021,600)	2,984,300)	2,778,700)
After Adjustment
Adjusted total capital	6,313,400)	5,076,000)	4,700,400)	3,660,704)	3,882,639)

¹ Operating lease liability (before adoption of FASB Topic 842). See details »

² Operating lease liabilities, current portion. See details »

³ Operating lease liabilities, long-term portion. See details »

⁴ Net deferred tax assets (liabilities). See details »

Download chart

Edwards Lifesciences Corp., adjusted net income

US$ in thousands

12 months ended:	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
As Reported
Net income	1,503,100)	823,400)	1,046,900)	722,200)	583,600)
Adjustments
Add: Deferred income tax expense (benefit)¹	(44,000)	(52,200)	10,500)	(21,200)	27,100)
Add: Increase (decrease) in allowance for doubtful accounts	(300)	900)	(200)	400)	(500)
Add: Other comprehensive income (loss), net of tax	3,400)	(5,100)	(17,500)	2,000)	65,700)
After Adjustment
Adjusted net income	1,462,200)	767,000)	1,039,700)	703,400)	675,900)

¹ Deferred income tax expense (benefit). See details »

Download chart

Edwards Lifesciences Corp. (NYSE:EW)

Adjustments to Financial Statements